Vivek Jain Increases ICUI Stake with 21,929-Share Purchase

Rhea-AI Filing Summary

Vivek Jain, Chairman and CEO of ICU Medical, Inc. (ICUI), reported purchases of company common stock on 08/14/2025. He acquired 2,378 shares at a weighted-average price of $112.1165 (purchases ranged $111.75–$112.435) and 19,551 shares at a weighted-average price of $112.9232 (purchases ranged $112.48–$113.435). Following these transactions, Mr. Jain beneficially owns 130,149 shares directly and 88,698 shares indirectly through a trust; a prior direct holding of 110,598 shares is shown prior to the second reported purchase line. The Form 4 was signed by an attorney-in-fact, Paula Darbyshire.

Positive

• CEO increased direct ownership through open-market purchases totaling 21,929 shares on 08/14/2025
• Transparent pricing disclosed with weighted-average prices and stated per-trade ranges ($111.75–$113.435)
• Filing shows compliance with Section 16 reporting and includes attorney-in-fact signature

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO purchases increased direct ownership, signaling management's capital deployment into company stock without disclosed disposition.

The report documents open-market purchases by the Chairman and CEO totaling 21,929 shares on a single date at weighted-average prices in the low $112 range. Such insider purchases are a concrete, non-speculative data point showing executive market activity and a modest increase in direct holdings to 130,149 shares. The filing includes weighted-average price ranges and an undertaking to provide per-trade details on request, which helps validate execution transparency. No derivative transactions or dispositions are reported.

Corporate Governance Expert

TL;DR: The CEO's purchases are disclosed properly on Form 4 and increase his direct stake, with filings executed by an attorney-in-fact.

The Form 4 shows compliance with Section 16 reporting: transaction codes, weighted-average prices, and an explicit statement that multiple trades compose each line. Beneficial ownership is itemized as direct and indirect (trust). The use of an attorney-in-fact to sign is documented, which is common for timely reporting. The filing contains no indications of departures, pledges, or option exercises.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Vivek

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CA 92673

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		P		2,378	A	$112.1165(1)	110,598	D
Common Stock	08/14/2025		P		19,551	A	$112.9232(2)	130,149	D
Common Stock								88,698	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $111.75 to $112.435 inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

2. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $112.48 to $113.435, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

	By: Paula Darbyshire, Attorney-in-Fact For: Vivek Jain	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Vivek Jain report on Form 4 for ICUI?

He reported purchases on 08/14/2025 of 2,378 shares at a weighted-average price of $112.1165 and 19,551 shares at $112.9232.

How many ICUI shares does Vivek Jain beneficially own after the reported transactions?

The filing shows 130,149 shares held directly following the transactions and 88,698 shares indirectly via a trust.

Were the share purchases executed at single prices?

No; the Form 4 states each reported price is a weighted average and purchases occurred at multiple prices within specified ranges.

Who signed the Form 4 for Vivek Jain?

The Form 4 was signed on behalf of Vivek Jain by Paula Darbyshire, Attorney-in-Fact on 08/14/2025.

Did the filing disclose any derivative transactions or stock dispositions?

No derivative transactions or dispositions are reported in the provided Form 4 content.